Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

Marcel Kool(German Cancer Research Center), Andrey Korshunov(German Cancer Research Center), Marc Remke(University Hospital Heidelberg), David Jones(Heidelberg University), Maria Schlanstein(German Cancer Research Center), Paul A. Northcott(University of Toronto), Yoon-Jae Cho(Stanford University), Jan Köster(Academic Medical Center), Antoinette Schouten‐van Meeteren(Academic Medical Center), Dannis G. van Vuurden(Cancer Center Amsterdam), Steven C. Clifford(Newcastle University), Torsten Pietsch(University of Bonn), André O. von Bueren(University Medical Center Hamburg-Eppendorf), Stefan Rutkowski(Universität Hamburg), Martin G. McCabe(Manchester Academic Health Science Centre), V. Peter Collins(University of Cambridge), L. Magnus Bäcklund(Karolinska University Hospital), Christine Haberler(Medical University of Vienna), Franck Bourdeaut(Institut Curie), Olivier Delattre(Institut Curie), François Doz(Délégation Paris 5), David W. Ellison(St. Jude Children's Research Hospital), Richard J. Gilbertson(St. Jude Children's Research Hospital), Scott L. Pomeroy(Boston Children's Hospital), Michael D. Taylor(SickKids Foundation), Peter Lichter(German Cancer Research Center), Stefan M. Pfister(University Hospital Heidelberg)
Acta Neuropathologica
February 22, 2012
Cited by 1,062Open Access
Full Text

Abstract

Medulloblastoma is the most common malignant brain tumor in childhood. Molecular studies from several groups around the world demonstrated that medulloblastoma is not one disease but comprises a collection of distinct molecular subgroups. However, all these studies reported on different numbers of subgroups. The current consensus is that there are only four core subgroups, which should be termed WNT, SHH, Group 3 and Group 4. Based on this, we performed a meta-analysis of all molecular and clinical data of 550 medulloblastomas brought together from seven independent studies. All cases were analyzed by gene expression profiling and for most cases SNP or array-CGH data were available. Data are presented for all medulloblastomas together and for each subgroup separately. For validation purposes, we compared the results of this meta-analysis with another large medulloblastoma cohort (n = 402) for which subgroup information was obtained by immunohistochemistry. Results from both cohorts are highly similar and show how distinct the molecular subtypes are with respect to their transcriptome, DNA copy-number aberrations, demographics, and survival. Results from these analyses will form the basis for prospective multi-center studies and will have an impact on how the different subgroups of medulloblastoma will be treated in the future.


Related Papers

No related papers found

Powered by citation graph analysis